Molecular mediators of hepatic steatosis and liver injury

Journal of Clinical Investigation

Volumn 114, Issue 2, 2004, Pages 147-152

  Browning, Jeffrey D ^a   Horton, Jay D ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADENOSINE TRIPHOSPHATE CITRATE LYASE; BINDING PROTEIN; CARBOHYDRATE RESPONSE ELEMENT BINDING PROTEIN; CARNITINE PALMITOYLTRANSFERASE; FATTY ACID; FATTY ACID SYNTHASE; HORMONE SENSITIVE LIPASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LIVER TYPE PYRUVATE KINASE; LONG CHAIN FATTY ACID; LONG CHAIN FATTY ACID ELONGASE; MALONYL COENZYME A; PYRUVATE KINASE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

CARBOHYDRATE RESPONSE ELEMENT; DNA RESPONSIVE ELEMENT; FATTY LIVER; HUMAN; INSULIN RESISTANCE; LIPID PEROXIDATION; LIPOGENESIS; LIVER FAILURE; LIVER INJURY; LIVER TRANSPLANTATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; UNITED STATES;

DISEASE PROGRESSION; FATTY LIVER; HUMANS; INSULIN RESISTANCE; LIPID PEROXIDATION; LIVER; MITOCHONDRIA; MULTIENZYME COMPLEXES; OBESITY; OXIDATIVE STRESS; PROTEIN-SERINE-THREONINE KINASES; TRIGLYCERIDES;

EID: 4043077961     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200422422     Document Type: Review

References (84)

1. Neuschwander-Tetri, B., and Caldwell, S. 2003. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology. 37:1202-1219.
2. Clark, J.M., Brancati, F.L., and Diehl, A.M. 2003. The prevalence and etiology of elevated aminotransferase levels in the United States. Am. J. Gastroenterol. 98:960-967.
3. Angulo, P. 2002. Nonalcoholic fatty liver disease. N. Engl. J. Med. 346:1221-1231.
4. Marchesini, G., et al. 2001. Nonalcoholic fatty liver disease a feature of the metabolic syndrome. Diabetes. 50:1844-1850.
5. Day, C.P., and James, O.F.W. 1998. Steatohepatitis: a tale of two "hits"? Gastroenterology. 114:842-845.
6. Nomura, H., et al. 1988. Prevalence of fatty liver in a general population in Okinawa, Japan. Jpn. J. Med. 27:142-149.
7. Hilden, M., Christoffersen, P., Juhl, E., and Dalgaard, J.B. 1977. Liver histology in a "normal" population - examination of 503 consecutive fatal traffic casualties. Scand. J. Gastroenterol. 12:593-597.
8. Bellentani, S., et al. 2000. Prevalence of and risk factors for hepatic steatosis in northern Italy. Ann. Intern. Med. 132:112-117.
9. Flegal, K.M., Ogden, C.L., Wei, R., Kuczmarski, R.L., and Johnson, C.L. 2001. Prevalence of overweight in US children: comparison of US growth charts from the Centers for Disease Control and Prevention with other reference values for body mass index. Am. J. Clin. Nutr. 73:1086-1093.
10. Rashid, M., and Roberts, E.A. 2000. Nonalcoholic steatohepatitis in children. J. Pediatr. Gastroenterol. Nutr. 30:48-52.
11. Browning, J.D., Kumar, K.S., Saboorian, M.H., and Thiele, D.L. 2004. Ethnic differences in the prevalence of cryptogenic cirrhosis. Am. J. Gastroenterol. 99:292-298.
12. Caldwell, S.H., Harris, D.M., Patrie, J.T., and Hespenheide, E.E. 2002. Is NASH underdiagnosed among African Americans? Am. J. Gastroenterol. 97:1496-1500.
13. Lewis, G.F., Carpentier, A., Adeli, K., and Giacca, A. 2002. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr. Rev. 23:201-229.
14. Wahren, J., Sato, Y., Ostman, J., Hagenfeldt, L., and Felig, P. 1984. Turnover and splanchnic metabolism of free fatty acids and ketones in insulin-dependent diabetics at rest and in response to exercise. J. Clin. Invest. 73:1367-1376.
15. Horton, J.D., Goldstein, J.L., and Brown, M.S. 2002. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109:1125-1131. doi:10.1172/JCI200215593.
16. Araya, J., et al. 2004. Increase in long-chain poly-unsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin. Sci. (Lond). 106:635-643.
17. Shimomura, I., Shimano, H., Korn, B.S., Bashmakov, Y., and Horton, J.D. 1998. Nuclear sterol regulatory element-binding proteins activate genes responsible for the entire program of unsaturated fatty acid biosynthesis in transgenic mouse liver. J. Biol. Chem. 273:35299-35306.
18. Koo, S.-H., Dutcher, A.K., and Towle, H.C. 2001. Glucose and insulin function through two distinct transcription factors to stimulate expression of lipogenic enzyme genes in liver. J. Biol. Chem. 276:9437-9445.
19. Stoeckman, A.K., and Towle, H.C. 2002. The role of SREBP-1c in nutritional regulation of lipogenic enzyme gene expression. J. Biol. Chem. 277:27029-27035.
20. Shimomura, I., et al. 1999. Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. Proc. Natl. Acad. Sci. U. S. A. 96:13656-13661.
21. Foretz, M., Guichard, C., Ferre, P., and Foufelle, F. 1999. Sterol regulatory element binding protein-1c is a major mediator of insulin action on the hepatic expression of glucokinase and lipogenesis-related genes. Proc. Natl. Acad. Sci. U. S. A. 96:12737-12742.
22. Brown, M.S., and Goldstein, J.L. 1997. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell. 89:331-340.
23. Horton, J.D., et al. 2003. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc. Natl. Acad. Sci. U. S. A. 100:12027-12032.
24. Shimano, H., et al. 1997. Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells. J. Clin. Invest. 99:846-854.
25. Shimomura, I., Bashmakov, Y., and Horton, J.D. 1999. Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J. Biol. Chem. 274:30028-30032.
26. Martin, R.J. 1974. In vivo lipogenesis, and enzyme levels in adipose tissue and liver tissues from pair-fed genetically obese and lean rats. Life Sci. 14:1447-1453.
27. Memon, R.A., Grunfeld, C., Moser, A.H., and Feingold, K. R. 1994. Fatty acid synthesis in obese insulin resistant diabetic mice. Horm. Metab. Res. 26:85-87.
28. Lam, T.K.T., et al. 2003. Mechanisms of the free fatty acid-induced increase in hepatic glucose production. Am. J. Physiol. Endociinol. Metab. 284:E863-E873.
29. Halaas, J.L., et al. 1995. Weight-reducing effects of the plasma protein encoded by the obese gene. Science. 269:543-546.
30. Yahagi, N., et al. 2002. Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lepob/Lepob mice. J. Biol. Chem. 277:19353-19357.
31. Abu-Elheiga, L., et al. 2000. The subcellular localization of acetyl-CoA carboxylase 2. Proc. Natl. Acad. Sci. U. S. A. 97:1444-1449.
32. McGarry, J.D., Mannaerts, G.P., and Foster, D.W. 1977. A possible role for malonyl-CoA in the regulation of hepatic fatty acid oxidation and ketogenesis. J. Clin. Invest. 60:265-270.
33. Abu-Elheiga, L., Matzuk, M.M., Abo-Hashema, K.A.H., and Wakil, S.J. 2001. Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. Science. 291:2613-2616.
34. Abu-Elheiga, L., Oh, W., Kordari, P., and Wakil, S.J. 2003. Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high-fat/high-carbohydrate diets. Proc. Natl. Acad. Sci. U. S. A. 100:10207-10212.
35. An, J., et al. 2004. Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance. Nat. Med. 10:268-274.
36. Yamashita, H., et al. 2001. A glucose-responsive transcription factor that regulates carbohydrate metabolism in the liver. Proc. Natl. Acad. Sci. U. S. A. 98:9116-9121.
37. Kawaguchi, T., Osatomi, K., Yamashita, H., Kabashima, T., and Uyeda, K. 2002. Mechanism for fatty acid "sparing" effect on glucose-induced transcription. Regulation of carbohydrace-responsive element-binding protein by Amp-activated protein kinase. J. Biol. Chem. 277:3829-3835.
38. Iizuka, K., Bruick, R.K., Liang, G., Horton, J.D., and Uyeda, K. 2004. Deficiency of carbohydrate response element binding protein (ChREBP) reduces lipogenesis as well as glycolysis. Proc. Nat. Acad. Sci. U. S. A. In press.
39. Tontonoz, P., Hu, E., and Spiegelman, B.M. 1994. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell. 79:1147-1156.
40. Edvardsson, U., et al. 1999. Rosiglitazone (BRL49653), a PPARgamma-selective agonist, causes peroxisome proliferator-like liver effects in obese mice. J. Lipid. Res. 40:1177-1184.
41. Chao, L., et al. 2000. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J. Clin. Invest. 106:1221-1228.
42. Kim, J.B., Wright, H.M., Wright, M., and Spiegelman, B.M. 1998. ADD1/SREBP-1 activates PPAR gamma through the production of endogenous ligand. Proc. Natl. Acad. Sci. U. S. A. 95:4333-4337.
43. Fajas, L., et al. 1999. Regulation of peroxisome proliferator-activated receptor gamma expression by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: implications for adipocyte differentiation and metabolism. Mol. Cell. Biol. 19:5495-5503.
44. Matsusue, K., et al. 2003. Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J. Clin. Invest. 111:737-747. doi:10.1172/JCI200317223.
45. Gavrilova, O., et al. 2003. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steacosis, triglyceride clearance, and regulation of body fat mass. J. Biol. Chem. 278:34268-34276.
46. Hardie, D.G. 2003. Minireview: The AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology. 144:5179-5183.
47. Cohen, P., et al. 2002. Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss. Science. 297:240-243.
48. Ntambi, J.M., et al. 2002. Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. Proc. Natl. Acad. Sci. U. S. A. 99:11482-11486.
49. Dobrzyn, P., et al. 2004. Stearoyl-CoA desaturase 1 deficiency increases fatty acid oxidation by activating AMP-activated protein kinase in liver. Proc. Natl. Acad. Sci. U. S. A. 101:6409-6414.
50. Hardie, D.G., Scott, J.W., Pan, D.A., and Hudson, E.R. 2003. Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett. 546:113-120.
51. Kawaguchi, T., Takenoshica, M., Kabashima, T., and Uyeda, K. 2001. Glucose and cAMP regulate the L-type pyruvate kinase gene by phosphorylation/dephosphorylation of the carbohydrate response element binding protein. Proc. Natl. Acad. Sci. U. S. A. 98:13710-13715.
52. Zhou, G., et al. 2001. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108:1167-1174. doi:10.1172/JCI200113505.
53. Lin, H.Z., et al. 2000. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat. Med. 6:998-1003.
54. Marchesini, G., et al. 2001. Metformin in non-alcoholic steatohepatitis. Lancet. 358:893-894.
55. Fryer, L.G., Parbu-Patel, A., and Carling, D. 2002. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J. Biol. Chem. 277:25226-25232.
56. Saha, A.K., et al. 2004. Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo. Biochem. Biophys. Res. Commun. 314:580-585.
57. Bajaj, M., et al. 2003. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes. 52:1364-1370.
58. Promrat, K., et al. 2004. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology. 39:188-196.
59. Neuschwander-Tetri, B.A., et al. 2003. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology. 38:1008-1017.
60. Hellerstein, M.K., Schwarz, J.M., and Neese, R.A. 1996. Regulation of hepatic de novo lipogenesis in humans. Annu. Rev. Nutr. 16:523-557.
61. Diraison, F., Dusserre, E., Vidal, H., Sothier, M., and Beylot, M. 2002. Increased hepatic lipogenesis but decreased expression of lipogenic gene in adipose tissue in human obesity. Am. J. Physiol. Endocrinol. Metab. 282:E46-E51.
62. Robertson, G., Leclercq, I., and Farrell, G.C. 2001. Nonalcoholic steatosis and steatohepatitis: II. Cytochrome P-450 enzymes and oxidative stress. Am. J. Physiol. Gastrointest. Liver Physiol. 281:G1135-G1139.
63. Lieber, C.S. 2004. CYP2E1: from ASH to NASH. Hepatol. Res. 28:1-11.
64. Mannaerts, G.P., Van Veldhoven, P.P., and Casteels, M. 2000. Peroxisomal lipid degradation via beta- and alpha-oxidation in mammals. Cell Biochem. Biophys. 32:73-87.
65. Garcia-Ruiz, C., Colell, A., Morales, A., Kaplowitz, N., and Fernandez-Checa, J.C. 1995. Role of oxidative stress generated from the mitochondrial electron transport chain and mitochondrial glutathione status in loss of mitochondrial function and activation of transcription factor nuclear factor-kappa B: studies with isolated mitochondria and rat hepatocytes. Mol. Pharmacol. 48:825-834.
66. Hensley, K., et al. 2000. Dietary choline restriction causes complex I dysfunction and increased H(2)O(2) generation in liver mitochondria. Carcinogenesis. 21:983-989.
67. Bergamini, C.M., Gambetti, S., Dondi, A., and Cervellati, C. 2004. Oxygen, reactive oxygen species and tissue damage. Curr. Pharm. Des. 10:1611-1626.
68. Yang, S., et al. 2000. Mitochondrial adaptations to obesity-related oxidant stress. Arch. Biochem. Biophys. 378:259-268.
69. Seki, S., et al. 2002. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J. Hepatol. 37:56-62.
70. Reddy, J.K., and Mannaerts, G.P. 1994. Peroxisomal lipid metabolism. Annu. Rev. Nutr. 114:343-370.
71. Caldwell, S.H., et al. 1999. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J. Hepatol. 31:430-434.
72. Berson, A., et al. 1998. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology. 114:764-774.
73. Perez-Carreras, M., et al. 2003. Defective hepatic mitochondrial respiratory chain in patients with non-alcoholic steatohepatitis. Hepatology. 38:999-1007.
74. Cortez-Pinto, H., Zhi Lin, H., Qi Yang, S., Odwin Da Costa, S., and Diehl, A.M. 1999. Lipids upregulate uncoupling protein 2 expression in rat hepatocytes. Gastroenterology. 116:1184-1193.
75. Johnson, E.F., Palmer, C.N., Griffin, K.J., and Hsu, M.H. 1996. Role of the peroxisome proliferator-activated receptor in cytochrome P450 4A gene regulation. FASEB J. 10:1241-1248.
76. Kersten, S., et al. 1999. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J. Clin. Invest. 103:1489-1498.
77. Tonsgard, J.H., and Getz, G.S. 1985. Effect of Reye's syndrome serum on isolated chinchilla liver mitochondria. J. Clin. Invest. 76:816-825.
78. Hermesh, O., Kalderon, B., and Bar-Tana, J. 1998. Mitochondria uncoupling by a long chain fatty acyl analogue. J. Biol. Chem. 273:3937-3942.
79. Esterbauer, H., Schaur, R.J., and Zollner, H. 1991. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. 11:81-128.
80. Gardner, H.W. 1989. Oxygen radical chemistry of polyunsaturated fatty acids. Free Radic. Biol. Med. 7:65-86.
81. Wagner, B.A., Buettner, G.R., and Bums, C.P. 1994. Free radical-mediated lipid peroxidation in cells: oxidizability is a function of cell lipid bis-allylic hydrogen content. Biochemistry. 33:4449-4453.
82. Infante, J.P., and Huszagh, V.A. 2000. Secondary carnitine deficiency and impaired docosahexaenoic (22:6n-3) acid synthesis: a common denominator in the pathophysiology of diseases of oxidative phosphorylation and beta-oxidation. FEBS Lett. 468:1-5.
83. Pan, M., et al. 2004. Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production. J. Clin. Invest. 113:1277-1287. doi:10.1172/JC1200419197.
84. Yamauchi, T., et al. 2003. Globular adiponectin protected ob/ob mice from diabetes and apoE-deficient mice from atherosclerosis. J. Biol. Chem. 278:2461-2468.